Organon & Co. (NYSE:OGN) Receives $20.80 Average PT from Analysts

Organon & Co. (NYSE:OGN - Get Free Report) has been assigned an average rating of "Hold" from the seven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $20.60.

A number of equities research analysts recently weighed in on OGN shares. Morgan Stanley lowered their price target on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a report on Wednesday. Barclays lowered their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th.

Institutional Trading of Organon & Co.

A number of large investors have recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB lifted its holdings in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after purchasing an additional 672 shares in the last quarter. Treasurer of the State of North Carolina boosted its position in Organon & Co. by 0.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company's stock worth $1,688,000 after acquiring an additional 710 shares during the last quarter. Beam Wealth Advisors Inc. boosted its position in Organon & Co. by 3.9% during the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company's stock worth $282,000 after acquiring an additional 717 shares during the last quarter. HighTower Advisors LLC grew its stake in Organon & Co. by 0.5% in the 4th quarter. HighTower Advisors LLC now owns 163,440 shares of the company's stock worth $2,439,000 after acquiring an additional 855 shares during the period. Finally, CIBC Asset Management Inc raised its holdings in Organon & Co. by 4.9% in the 4th quarter. CIBC Asset Management Inc now owns 25,523 shares of the company's stock valued at $381,000 after acquiring an additional 1,184 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Remove Ads

Organon & Co. Price Performance

OGN stock traded down $1.20 on Friday, reaching $11.45. 1,356,864 shares of the company's stock were exchanged, compared to its average volume of 2,626,705. The stock has a fifty day moving average of $14.78 and a 200-day moving average of $15.78. The firm has a market cap of $2.95 billion, a PE ratio of 3.44, a P/E/G ratio of 0.90 and a beta of 0.73. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a twelve month low of $11.05 and a twelve month high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. As a group, equities analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 9.79%. Organon & Co.'s dividend payout ratio (DPR) is 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.